---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-023625"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-06-02T10:09:32+00:00"
generated_at: "2026-06-02T10:11:09.321948+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Gyre Therapeutics posts updated corporate presentation; specific content not available in filing excerpt

## Summary
- Presentation dated June 2026 made available on company's website on June 1, 2026.
- Presentation describes Gyre as a biopharma company focused on fibrosis, inflammatory diseases, and cancer.
- Filing includes only the title slide; full presentation content is not included in the provided exhibit text.
- Investors should refer to the full presentation on the company's website for detailed updates.

## SEC filing metadata
- accession: 0001140361-26-023625
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-06-02T10:09:32+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126023625/0001140361-26-023625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126023625/ef20075381_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-023625
- JSON: https://secwatch.observer/filing/0001140361-26-023625.json
- Plain text: https://secwatch.observer/filing/0001140361-26-023625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.